Could Rheumatoid Arthritis Be Preventable in Some People?

Most rheumatoid arthritis (RA) research focuses on managing the disease once it's already established, since there hasn't been strong evidence that any intervention can actually stop it from developing in the first place. Palindromic rheumatism, a condition marked by short, intermittent episodes of joint inflammation that flare for a few days and then resolve completely on their own, has long been recognized as a kind of early warning sign, since roughly half of people with this condition go on to develop persistent rheumatoid arthritis. That made it a natural place to test whether early intervention could actually change the disease's course.

Researchers from Hospital Clinic de Barcelona, IDIBAPS, and the Institute of Advanced Chemistry of Catalonia ran a randomized, open-label trial across 14 hospitals in Spain, enrolling 70 patients with palindromic rheumatism. Half received abatacept, a biologic drug that works by blocking a specific costimulatory signal needed to fully activate T cells, given as weekly subcutaneous injections for the first year and every two weeks in the second year. The other half received standard oral hydroxychloroquine, the medication most commonly used for this condition today.

The results, published in Nature Medicine in late June 2026, were substantial. Only 20% of patients treated with abatacept went on to develop persistent, full-blown rheumatoid arthritis over the two-year study, compared with 50% of those on hydroxychloroquine, meaning abatacept cut that risk by more than half. Patients on abatacept also showed reduced arthritis progression and improved symptoms overall compared with the hydroxychloroquine group.

This is an early but genuinely important shift in how RA might eventually be approached. Rather than waiting for the full disease to take hold and then managing it, this trial suggests that identifying high-risk patients, in this case through palindromic rheumatism, and treating them proactively with the right drug could meaningfully change whether the disease develops at all, not just how severe it becomes afterward.

It's worth keeping the scale of this trial in perspective. Seventy patients across two years is a solid proof of concept, but it's not yet the kind of large, multi-country trial that would typically support a formal treatment guideline change. Still, for anyone diagnosed with palindromic rheumatism, or with a family history of RA and early joint symptoms that come and go, this is worth raising with a rheumatologist, since it points toward a real, evidence-backed conversation about prevention rather than just watchful waiting.